CTRI/2021/04/033014
Completed
Phase 3
Clinical study to evaluate the efficacy and safety of vitimelin tablet and vitimelin oil in vitiligo w.s.r. to shwitra
DrVasishths Ayuremedies0 sites30 target enrollmentTBD
ConditionsHealth Condition 1: L80- Vitiligo
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: L80- Vitiligo
- Sponsor
- DrVasishths Ayuremedies
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\-Children of either gender aged group between 10 \- 16 years.
- •2\- Children having classical sign and symptom and diagnosed as vitiligo / Shwitra.
- •3\- Patient should be capable of obeying the instruction related to course of therapy.
Exclusion Criteria
- •1\- Children below 10 years and above 16 years of age.
- •2\- Patches more than 30% of the body, Broad continuous irregular patches.
- •3\- Children with albinism will be excluded.
- •4\- White anesthetic spot which are characterized of leprosy.
- •5\- Patches in genital area and only lip area are excluded from the study.
- •6\- Patient not fulfilling the inclusion criteria.
- •7\- Patient suffering from any other known systemic and chronic disease / Autoimmune
- •8\- Patient not willing to give consent for participation in the Research study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasisPsoriasisJPRN-jRCT2080220313Mitsubishi Tanabe Pharma Corporation
Completed
Phase 2
A study for Under eye dark circlesCTRI/2022/09/045732Transformative Learning Solutions Pvt Ltd32
Active, not recruiting
Not Applicable
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AEUCTR2005-003552-35-DEOctapharma AG116
Completed
Phase 2
Clinical study on Dabur gel in reduction of oral malodor.Health Condition 1: R196- HalitosisCTRI/2021/07/034750Dabur India limited161
Active, not recruiting
Not Applicable
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AIdiopathic thrombocytopenic purpura, in adults actively bleeding or at high risk bleeding.MedDRA version: 7.0Level: LLTClassification code 10021245EUCTR2005-003552-35-ATOctapharma AG116